ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

Shots:

• The CUSTOMIZE study will evaluate the two-drug regimen consisting ViiV’s Cabotegravir and Janssen’s Edurant (rilpivirine) in patients with HIV with suppressed viral load and no resistance to cabotegravir or rilpivirine
• In Apr’2019, the US FDA has accepted NDA filing of long-acting dual-drug injectable regimen and has granted PR to NDA with its expected PDUFA date as Dec 29, 2019
• Edurant is an antiretroviral therapy indicated to treat HIV-1 in patients aged ≥ 12 yrs. Cabotegravir is an investigational therapy, being evaluated as an oral therapy & LA injectable for the treatment & prevention of HIV infection

Click here to read full press release/ article | Ref: GSK | Image: Twitter